Fu Jian-hua

Biography

Dr. Jian-Hua Fu is the professor of thoracic cancers and director of Guangdong Esophageal Cancer Institute. Dr. Fu obtained his Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 1987 and 2002, respectively, He is one of the most skilled thoracic surgeons in China, especially in the field of minimally invasive esophagectomy. He is the leading specialist in the diagnosis and treatment of Chinese esophageal cancers. He is currently a member of the standing committee of Chinese Anti-Cancer Association (CACA) of Esophageal Cancer, a member of the standing executive committee of Chinese Society of Clinical Oncology (CSCO), a member of Chinese Society for Thoracic and Cardiovascular Surgery (CSTCS), vice-president of Chinese Association of Thoracic Surgeons, president of Guangdong Anti-Cancer Association of Esophageal Cancer, vice-president of Guangdong Medical Association of Oncology. He was rewarded the second class of Guangdong Award for the Scientific and Technological Advancement in 2006, and the third class in 1999, respectively. He has published more than 40 papers in world famous journals, such as Ann Surg, Ann Oncol, J Thorac Oncol, Br J Surg, Br J Cancer, and et al, and over 100 papers in Chinese core journals as the corresponding author or first author.

Research Interest

My primary interest is the comprehensive treatment of esophageal squamous cell carcinomas (ESCCs), and a series of clinical and translational studies were conducted on it. A randomized controlled multi-centre Phase-III trial (Trial registration: NCT01216527) to compare two treatment strategies for ESCC patients at advanced stage, neo-adjuvant chemoradiotherapy (CRT) plus surgery and surgery alone, has completed patient enrollment in 2014. A preliminary analysis of the clinical trial performed in 2013 showed that neo-adjuvant CRT significantly improved R0 resection rate. The cohort of patients receiving neo-adjuvant CRT followed by surgery exhibited better overall and disease-free survival than that of surgery alone. A new Phase-III trial comparing two neo-adjuvant CRT regimens, docetaxol plus cisplatin and vinorelbine plus cisplatin was started in July, 2015, which intends to further optimize ESCC neo-adjuvant CRT strategy. Along with the clinical trial, mRNA and miRNA microarray and high-throughput sequencing studies of pre-treatment tumour biopsies are conducted in ESCC patients who received neo-adjuvant CRT so as to identify molecular markers for patients’ CRT response and survival prediction. Prediction models based on mRNA and miRNA expression were built up, which exhibited good sensitivity and specificity in classifying responders and non-responders after neo-adjuvant CRT.